<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03758950</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 17-1936</org_study_id>
    <secondary_id>R01HL142671</secondary_id>
    <nct_id>NCT03758950</nct_id>
  </id_info>
  <brief_title>Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2</brief_title>
  <acronym>IMPROVE2</acronym>
  <official_title>Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeffrey Glassberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study team proposes a triple-blind, placebo-controlled, phase II clinical trial of
      once-daily inhaled mometasone for 48 weeks (with 4-week washout at study completion) in
      individuals with Sickle Cell Disease (SCD) who report episodic cough or wheeze (ECW) but do
      not have asthma. Patients will be recruited from and followed in SCD clinics at participating
      sites. The primary endpoint will be a reduction in sVCAM level of 20% or more in comparison
      to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose rationale: Mometasone furoate 220mcg dry powder inhalation is a low-moderate ICS dose
      that can be given once daily. Higher doses can have systemic effects and systemic
      glucocorticoids can precipitate rebound SCD pain when discontinued.

      Adaptive, covariate-balanced randomization: While the sample size of the study will be fixed
      at 80 participants, instead of standard blocked or stratified randomization, the study team
      will use adaptive covariate-balanced randomization to minimize imbalance of important
      covariates. This will reduce the need to use multivariable techniques (which perform poorly
      in small samples) to adjust post hoc for differences between treatment groups. Covariates
      will include age, use of hydroxyurea, previous rate of Emergency Department (ED) utilization
      for SCD pain, and recruitment site.

      Follow up Schedule: There will be in-person visits every 8 weeks. In addition, a blinded
      research coordinator will contact participants by phone at 2-weeks and 4-weeks after
      enrollment and 4-weeks after each in-person follow up to encourage protocol adherence and
      collect data about adverse events and healthcare utilization.

      Post-protocol observation period: The study will be complete at 48 weeks. A final follow up
      visit will occur at 52 weeks (4-weeks after study protocol completed) to collect pain diary
      and adverse event data and to identify the proportion of the ICS group who want to continue
      ICS. In the event that individuals wish to continue ICS, the PI will contact the
      participant's treating physician to discuss.

      Data elements: A wide range of clinical and translational data will be collected during the
      study. Baseline data will include demographic and clinical variables regarding SCD severity,
      previous complications and respiratory surveys. Blood will be collected for standard-of-care
      labs and analysis of serum inflammatory cytokines. Pulmonary function testing including
      spirometry and Exhaled Nitric Oxide (eNO) will be performed. Health related quality of life
      will be collected via ASCQ-Me survey. Patients will also be followed with follow-up phone
      calls and prospective chart review for one year to identify hospital visits and other SCD
      complications.

      Procedures for collection of clinical and laboratory data: Data collection and management:
      Case report forms are provided as an appendix. Data will be entered into a REDCap database,
      which will be monitored by the Data Coordinating Team (DCT) (led by Co-I Gelijns) for
      completion and timeliness.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Quadruple blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Soluble Vascular Cell Adhesion Molecule (sVCAM) level</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>Change in sVCAM level at one year compared to baseline. sVCAM is a biomarker used as a surrogate for red blood cell (RBC) adhesivity and overall disease severity in SCD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reticulocyte Count level</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>Change in Reticulocyte Count level at one year compared to baseline. Reticulocyte count is a secondary measure of hemolysis. In SCD, it is more reflective of hemolytic burden than any other clinically available laboratory test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Free Hemoglobin level</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>Change in Free Hemoglobin level at one year compared to baseline. Free hemoglobin is a direct measure of hemolysis. It is more reflective of hemolytic burden than reticulocyte count but it is not available for clinical use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDH level</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>Change in LDH level at one year compared to baseline. LDH is a marker of hemolysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin (Direct and Indirect) level</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>Change in Bilirubin level at one year compared to baseline. Bilirubin measure of hemolysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>Change in Hemoglobin level at one year compared to baseline. Hemoglobin is a clinical lab test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocyte Count level</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>Change in Leukocyte level at one year compared to baseline. Leukocyte is a clinical lab test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Count level</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>Change in Platelet count level at one year compared to baseline. Platelet count is a clinical lab test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exhaled Nitric Oxide</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>Change in eNO level at one year as compared to baseline. Nitric oxide is a marker of eosinophilic pulmonary inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me) survey</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>ASCQ-Me is a patient-reported outcome measurement system that evaluates and monitors the physical, mental, and social well-being of adults with sickle cell disease (SCD). ASCQ-Me uses a T-score metric in which 50 is the mean of the reference population and 10 is the standard deviation (SD) of that population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Adherence Self-Report Scale for Asthma (MARS-A)</measure>
    <time_frame>At one year</time_frame>
    <description>MARS-A is a 10-item, self-reported measure of adherence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Natriuretic Peptide</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>Change in brain natriuretic peptide at one year compared to baseline. Brain natriuretic peptide is a measure of atrial stretch.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometry</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>Change in spirometry at one year compared to baseline. Spirometry is the measure of airflow and lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score</measure>
    <time_frame>Up to one year</time_frame>
    <description>Pain score on a zero to ten scale reflects &quot;yesterday's worst pain&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ED Visits for SCD Pain</measure>
    <time_frame>One year</time_frame>
    <description>Measure of morbidity and healthcare utilization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number Hospitalizations for SCD Pain</measure>
    <time_frame>One year</time_frame>
    <description>Measure of morbidity and healthcare utilization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Observation Unit Admission for SCD Pain</measure>
    <time_frame>One year</time_frame>
    <description>Measure of morbidity and healthcare utilization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Overnight Stays for SCD Pain</measure>
    <time_frame>One year</time_frame>
    <description>Measure of morbidity and healthcare utilization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Outpatient Infusion Visits for SCD Pain</measure>
    <time_frame>One year</time_frame>
    <description>Measure of morbidity and healthcare utilization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Pneumonia Episodes</measure>
    <time_frame>One year</time_frame>
    <description>Measure of morbidity and healthcare utilization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ICU Admissions</measure>
    <time_frame>One year</time_frame>
    <description>Measure of morbidity and healthcare utilization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Deaths</measure>
    <time_frame>One year</time_frame>
    <description>Measure of disease severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>O-Link Inflammation Panel Serum</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>Change in O-Link Inflammation Panel Serum at one year compared to baseline. A 92 analyte panel of key molecules involved in inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>O-Link Inflammation Panel Sputum</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>Change in O-Link Inflammation Panel Sputum at one year compared to baseline. Inflammation panel performed on sputum supernatant will be a measure of pulmonary inflammatory signatures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiplex Cytokine Panel Serum</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>Change in Multiplex Cytokine Panel Serum at one year compared to baseline. Key inflammatory mediators including interleukins, selectins, interferon and TNF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum frequency of activated monocytes CyTOF</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>Change in Sputum frequency of activated monocytes CyTOF at one year compared to baseline. Measure of pulmonary inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum Frequency of Aged Neutrophils CyTOF</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>Change in Sputum Frequency of Aged Neutrophils CyTOF at one year compared to baseline. Measure of pulmonary inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum Immune Cell Subpopulations CyTOF</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>Change in Sputum Immune Cell Subpopulations CyTOF at one year compared to baseline. Frequencies of all immune subpopulations will be calculated to identify pulmonary inflammation signatures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum Immune Cell Subpopulations CyTOF</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>Change in Sputum Immune Cell Subpopulations CyTOF at one year compared to baseline. Measure of pulmonary inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole Blood Frequency of Aged Neutrophils CyTOF</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>Change in Whole Blood Frequency of Aged Neutrophils CyTOF at one year compared to baseline. Measure of pulmonary inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole Blood Immune Cell Subpopulations CyTOF</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>Change in Whole Blood Immune Cell Subpopulations CyTOF at one year compared to baseline. Frequencies of all immune subpopulations will be calculated to identify pulmonary inflammation signatures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-Minute Walk Test</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>Change in 6-Minute Walk Test at one year compared to baseline. The distance covered over a time of 6 minutes. Measure of cardiopulmonary exercise reserve.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once daily inhaled placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inhaled Mometasone Furoate 220 mcg DPI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily inhaled placebo for 48 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone</intervention_name>
    <description>Inhaled Mometasone for 48 weeks (with 4-week washout at study completion)</description>
    <arm_group_label>Mometasone</arm_group_label>
    <other_name>Inhaled Mometasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants age 18 and older with severe SCD phenotypes (Hb SS and SÎ²thalassemia0):

          -  Do not have asthma (see exclusion criteria)

          -  Not currently having a painful crisis (as defined by validated pain diary questions)

          -  Do not have acute respiratory symptoms

          -  Report of recent ECW (answers &quot;Yes&quot; to any question in Box 1)

          -  Participant is already medically optimized (i.e. already on maximum dose hydroxyurea
             unless contraindicated and not undergoing medication titration).

        Exclusion Criteria:

          -  Participant screens positive for possible undiagnosed asthma (Box 2)

          -  Pregnant or planning to become pregnant

          -  &gt; 15 ED visits for SCD pain over the previous 12 months (due to concern for
             multi-factorial pain that may be less responsive to SCD therapies)

          -  Have been discharged from the hospital within the previous 7 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Glassberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey Glassberg, MD</last_name>
    <phone>212-241-3650</phone>
    <email>jeffrey.glassberg@mountsinai.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cindy Clesca, BA</last_name>
    <phone>212-824-8057</phone>
    <email>cindy.clesca@mountsinai.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mount Sinai St Luke's</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeffrey Glassberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Glassberg, MD</last_name>
      <phone>212-241-3650</phone>
      <email>jeffrey.glassberg@mountsinai.org</email>
    </contact>
    <contact_backup>
      <last_name>Cindy Clesca, BA</last_name>
      <phone>212-824-8057</phone>
      <email>cindy.clesca@mountsinai.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Glassberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 28, 2018</study_first_submitted>
  <study_first_submitted_qc>November 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2018</study_first_posted>
  <last_update_submitted>January 3, 2020</last_update_submitted>
  <last_update_submitted_qc>January 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Jeffrey Glassberg</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Sickle Cell</keyword>
  <keyword>Inhaled Steroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

